微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 44% | -6.07% | -2.51% | 86/159 | 48.66% | 恩华药业 | 71.67% | 行业排名> |
| 2026-03-31 | 45.13% | -3.5% | 0.05% | 87/159 | 50.28% | 海创药业 | 97.34% | 行业排名> |
| 2025-12-31 | 45.11% | -5.09% | -4.14% | 88/159 | 50.37% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 47.06% | -3.72% | 0.46% | 81/159 | -2.12% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 46.84% | -1.15% | 0.15% | 82/159 | 15.05% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 46.77% | -4.91% | -1.59% | 76/159 | 31.79% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 47.53% | -4.82% | -2.76% | 85/159 | 51.61% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 48.88% | -5.59% | 3.14% | 80/159 | 22.43% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 47.39% | -10.33% | -3.65% | 83/159 | 32.96% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 49.18% | -8.4% | -1.5% | 79/159 | 51.47% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 49.93% | -5.62% | -3.55% | 79/159 | 51.31% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 51.77% | -6.89% | -2.04% | 70/159 | 32.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 52.85% | -1.21% | -1.57% | 70/159 | 38.22% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 53.69% | -1.97% | 1.49% | 70/159 | 52.66% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 52.9% | -12.11% | -4.85% | 78/159 | 53.51% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 55.6% | -6.52% | 3.94% | 67/159 | 5.67% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 53.49% | -7.82% | -2.32% | 73/159 | 20.91% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 54.77% | -4.32% | -9.02% | 71/159 | 54.06% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 60.2% | 1.04% | 1.21% | 63/159 | 54.9% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 59.48% | 3.12% | 2.49% | 54/159 | 46.49% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 58.03% | 4.88% | 1.38% | 62/159 | 46.97% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 57.24% | 15.51% | -3.93% | 59/159 | 53.79% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 59.58% | -5.69% | 3.29% | 59/159 | -147.51% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 57.68% | -3.8% | 4.25% | 55/159 | 56.06% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 55.33% | -7.81% | 11.66% | 62/159 | 53.85% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 49.55% | -12.35% | -21.56% | 64/159 | 54.83% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 63.17% | 3.66% | 5.36% | 50/159 | -1232.76% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 59.96% | 8.24% | -0.1% | 46/159 | 54.86% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 60.02% | 8.33% | 6.17% | 47/159 | 54.88% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 56.53% | 7.83% | -7.24% | 50/159 | 50.75% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 60.94% | 1.15% | 10.02% | 49/159 | -210.26% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 55.39% | -5.85% | -0.02% | 50/159 | 53.75% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 55.41% | -2.7% | 5.68% | 50/159 | 53.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 52.43% | -3.45% | -12.98% | 52/159 | 53.78% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 60.25% | -8.9% | 2.4% | 42/159 | 52.25% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 58.83% | -11.07% | 3.32% | 30/159 | 48.76% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 56.94% | -12.77% | 4.86% | 34/159 | 47.61% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 54.3% | -15.08% | -17.89% | 32/159 | 46.62% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 66.13% | -10.67% | -0.04% | 22/159 | 48.17% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 66.16% | -13.93% | 1.35% | 16/159 | 45.83% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 65.28% | -15.01% | 2.08% | 18/159 | 45.93% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 63.95% | -16.93% | -13.62% | 17/159 | 43.86% | 微芯生物 | 97.46% | 行业排名> |